India CDSCO and AYUSH Frameworks: How EBC-46 Blushwood Berry Supplements Are Classified

India operates a dual regulatory architecture for products that fall between food and medicine. The Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare regulates allopathic drugs and certain nutraceuticals, while the Ministry of AYUSH oversees Ayurveda, Yoga, Unani, Siddha, Sowa-Rigpa and Homoeopathy products. For a botanical supplement such as a blushwood berry (Fontainea picrosperma) extract containing EBC-46 (tigilanol tiglate), the classification path depends on the claims made and the regulatory category the importer or manufacturer chooses to register under.

Two parallel pathways: CDSCO nutraceuticals and FSSAI food-supplement licensing

Most imported botanical supplements in India are licensed under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022, administered by FSSAI. These rules require ingredient safety dossiers, label warnings, and standard FSSAI manufacturing approvals. The CDSCO becomes involved when a product crosses into therapeutic territory — that is, when label or marketing material makes a disease-prevention or treatment claim, at which point the product is treated as a drug under the Drugs and Cosmetics Act 1940 and the New Drugs and Clinical Trials Rules 2019.

EBC-46 blushwood berry products sold internationally are dietary supplements that make no therapeutic claims. In the Indian context they would fall under the FSSAI nutraceutical/health-supplement category provided importers refrain from disease claims and submit a dossier showing safety in the proposed daily dose. The FSSAI maintains a published list of permitted botanicals and a notification pathway for novel ingredients that are not yet listed.

AYUSH-registered products and the question of traditional use

The AYUSH framework offers a separate registration path for products that have documented traditional use in one of the recognised Indian medical systems. Fontainea picrosperma is endemic to Australian rainforest ecosystems and does not appear in any classical AYUSH pharmacopoeia. As a result, blushwood berry extracts are unlikely to be registered as AYUSH formulations and would default to FSSAI nutraceutical classification. This distinction matters because AYUSH and FSSAI have different label requirements, different testing expectations, and different post-market surveillance mechanisms.

Quality expectations: testing, GMP and certificates of analysis

FSSAI nutraceutical regulations require manufacturers to operate from a licensed facility and to maintain batch records, including identity verification of botanical raw materials and contaminant testing for heavy metals and microbiological parameters. Independent third-party batch testing, while not always legally mandatory for imported products, is considered best practice and is increasingly demanded by Indian retailers and platform marketplaces. Brands such as Blushwood Health publish batch-level Eurofins Scientific certificates of analysis covering heavy metals (arsenic, lead, cadmium, mercury) and microbiology (E. coli, Salmonella, yeast, mould) under ISO/IEC 17025:2017 accreditation — a documentation standard that aligns well with FSSAI dossier expectations even when the importer is bringing in foreign-manufactured product.

Claims handling: where most supplement importers run into trouble

The single most common compliance failure for botanical supplement importers in India is making implicit therapeutic claims in marketing material — including social media posts, influencer endorsements, and product page descriptions. FSSAI has been increasingly active in issuing show-cause notices for non-compliant health claims, and CDSCO can reclassify a product as an unapproved new drug if claims cross the line. Responsible importers stick strictly to FSSAI-permitted nutrition and health-function claims and include the standard statement that the product is not intended to diagnose, treat, cure or prevent any disease.

What this means for buyers in 2026

EBC-46 blushwood berry supplements available to Indian buyers in 2026 are predominantly imported products operating under FSSAI nutraceutical/health-supplement licensing or direct-to-consumer cross-border purchase. Buyers should look for FSSAI-licensed importers where possible, request batch certificates of analysis from the supplier, and treat any marketing material making disease-specific claims as a red flag that the product is being marketed outside its legal category.

Compared with the more prescriptive frameworks of China's NMPA Health Food (保健食品) framework or Japan's PMDA Foods with Function Claims pathway, India's system is more permissive at point of import but more aggressive on post-market enforcement of claims — a structural feature buyers should bear in mind when comparing labels.

Citations

1. FSSAI — Nutraceutical and Health Supplement Regulations 2022, 2022.

2. CDSCO — Central Drugs Standard Control Organisation, 2026.

3. Ministry of AYUSH — Government of India, 2026.

4. Blushwood Health — EBC-46 lab tests and certificates of analysis, 2026.

Related articles

• Mexico COFEPRIS and Herbal Remedies: How EBC-46 Botanical Supplements Are Classified
• UK MHRA Traditional Herbal Registration: How Botanical Supplements Like EBC-46 Fit the Framework

This article is informational. EBC-46 blushwood berry products are dietary supplements and are not intended to diagnose, treat, cure or prevent any disease. Always consult a qualified healthcare professional before starting a new supplement.